Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{205521,
        author = {Vivek Kumar Pandey},
        title = {LIPOSOMAL DRUG DELIVERY SYSTEM FOR OCULAR APPLICATION},
        journal = {International Journal of Innovative Research in Technology},
        year = {2026},
        volume = {13},
        number = {1},
        pages = {7191-7195},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=205521},
        abstract = {Ocular drug delivery remains a major pharmaceutical challenge because the eye is protected by highly efficient anatomical, physiological, and biochemical barriers. Conventional eye drops are convenient and non-invasive, but their bioavailability is generally poor due to tear dilution, blinking, nasolacrimal drainage, corneal epithelial resistance, and short precorneal residence time. These limitations increase dosing frequency, reduce patient compliance, and may cause local or systemic adverse effects. Liposomal drug delivery systems offer an important nanocarrier-based strategy to overcome these problems. Liposomes are spherical phospholipid vesicles with an aqueous core and lipid bilayer, allowing incorporation of both hydrophilic and lipophilic drugs. Their similarity to biological membranes provides high biocompatibility, while their vesicular structure supports drug protection, sustained release, and improved interaction with ocular tissues. Surface-modified liposomes, especially cationic liposomes, are particularly useful for topical ocular delivery because they interact electrostatically with the negatively charged mucin and corneal surface. This article review soculardelivery barriers, liposomal formulation principles, preparation methods, characterization parameters, evaluation techniques, therapeutic applications, marketed lipid-based products, and future research directions. The discussion shows that liposomal ocular systems may be useful in glaucoma, dry eye disease, ocular infections, inflammation, age-related macular degeneration, and diabetic retinopathy. However, formulation stability, sterilization, manufacturing scale-up, regulatory requirements, and long-term safety must be addressed for broader clinical translation.1,2,3},
        keywords = {Liposomes, ocular drug delivery, nanocarriers, cationic liposomes, sustained release, corneal permeation, ophthalmic formulation.},
        month = {June},
        }